Health issues in oral contraception: risks, side effects and health benefits

References

• ACOG Committee on Practice Bulletins–Gynecology. ACOG practice bulletin. No. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet. Gynecol.107(6), 1453–1472 (2006).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. US Medical Eligibility Criteria for Contraceptive Use, 2010 Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition MMWR Early Release59, 1–88 (2010).
   Google Scholar
• Kaunitz A. Hormonal contraception in women of older reproductive age. N. Engl. J. Med.358, 1262–1270 (2008).
   PubMed Web of Science ®Google Scholar
• Sidney S, Siscovick DS, Petitti DB et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation98, 1058–1063 (1998).
   PubMed Web of Science ®Google Scholar
• Schwartz SM, Petitti DB, Siscovick DS et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke29, 2277–2284 (1998).
   PubMed Web of Science ®Google Scholar
• Cardoso F, Polonia J, Santos A, Silva-Carvalho J, Ferreira-de-Almeida J. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int. J. Gynaecol. Obstet.59, 237–243 (1997).
   PubMed Web of Science ®Google Scholar
• Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin–aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J. Clin. Endocrinol. Metab.80(6), 1816–1821 (1995).
   PubMed Web of Science ®Google Scholar
• White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17β-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation112(13), 1979–1984 (2005).
   PubMed Web of Science ®Google Scholar
• Shulman LP. A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel , and micronized progesterone. J. Womens Health (Larchmt).15(5), 584–590 (2006).
   PubMed Web of Science ®Google Scholar
• Jick S, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case–control study using United States claims data. BMJ342, d2151 (2011).
   PubMed Web of Science ®Google Scholar
• Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case–control study based on UK General Practice Research Database. BMJ342, d2139 (2011).
   PubMed Web of Science ®Google Scholar
• Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organ. Tech. Rep. Ser.877(i–vii), 1–89 (1998).
   Web of Science ®Google Scholar
• Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur. J. Contracept. Reprod. Health Care4(2), 67–73 (1999).
   PubMedGoogle Scholar
• Tanis BC, van den Bosch MA, Kemmeren JM et al. Oral contraceptives and the risk of myocardial infarction. N. Engl. J. Med.345(25), 1787–1793 (2001).
   PubMed Web of Science ®Google Scholar
• Petitti DB. Clinical practice. Combination estrogen–progestin oral contraceptives. N. Engl. J. Med.349(15), 1443–1450 (2003).
   PubMed Web of Science ®Google Scholar
• MacClellan LR, Giles W, Cole J et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke38(9), 2438–2445 (2007).
   PubMed Web of Science ®Google Scholar
• Becker WJ. Use of oral contraceptives in patients with migraine. Neurology53(4 Suppl. 11), S19–SS2 (1999).
   Google Scholar
• Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR. Body mass index, weight, and oral contraceptive failure risk. Obstet. Gynecol.105(1), 46–52 (2005).
   PubMed Web of Science ®Google Scholar
• Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil. Steril.77(2 Suppl. 2), S13–S18 (2002).
   PubMed Web of Science ®Google Scholar
• Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Farmer RD. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur. J. Contracept. Reprod. Health Care5(4), 265–274 (2000).
   PubMedGoogle Scholar
• Sidney S, Petitti DB, Soff GA et al. Venous thromboembolic diseasein users of low-estrogen combined estrogen–progestin oral contraceptives. Contraception70, 3–10 (2004).
   PubMed Web of Science ®Google Scholar
• Walker AM. Newer oral contraceptives and the risk of venous thromboembolism. Contraception57(3), 169–181 (1998).
   PubMed Web of Science ®Google Scholar
• Hennessy S, Berlin JA, Kinman JL, Margolis DJ, Marcus SM, Strom BL. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception64(2), 125–133 (2001).
   PubMed Web of Science ®Google Scholar
• Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ323(7305), 131–134 (2001).
   PubMed Web of Science ®Google Scholar
• Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet358(9291), 1427–1429 (2001).
   PubMed Web of Science ®Google Scholar
• Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception73(3), 223–228 (2006).
   PubMed Web of Science ®Google Scholar
• Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception76(1), 4–7 (2007).
   PubMed Web of Science ®Google Scholar
• Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet. Gynecol.109(2 Pt 1), 339–346 (2007).
   PubMed Web of Science ®Google Scholar
• The ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum. Reprod. Update11(5), 51525 (2005).
   Google Scholar
• Yonkers KA, Brown C, Pearlstein TB et al. Efficacy of a new lowdose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet.Gynecol.106, 492–501 (2005).
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet371, 303–314 (2008).
   PubMed Web of Science ®Google Scholar
• Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives: a practitioner’s guide to meta-analysis. Hum. Reprod.12, 1851–1863 (1997).
   PubMed Web of Science ®Google Scholar
• Oelkers W, Foidart JM, Dombrovicz N et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J. Clin. Endocrinol. Metab.80, 1816–1821 (1995).
   PubMed Web of Science ®Google Scholar
• Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst. Rev.4, CD001125 (2003).
   Google Scholar
• Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst. Rev.2, CD006586 (2009).
   Google Scholar
• Willis SA, Kuehl TH, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary–ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception74(2), 100–103 (2006).
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Lynch AM, Hughes HD, Cedars MI, Smith DL. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am. J. Obstet. Gynecol.190(4), 943–951 (2004).
   PubMed Web of Science ®Google Scholar
• Baerwald AR, Olatunbosun OA, Pierson RA. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptiveuse. Contraception70(5), 371–377 (2004).
   PubMed Web of Science ®Google Scholar
• Coffee AL, Kuehl TJ, Willis SA, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am. J. Obstet. Gynecol.195(5), 1311–1319 (2006).
   PubMed Web of Science ®Google Scholar
• Vandever MA, Kuehl TJ, Sulak PJ et al. Evaluation of pituitary–ovarian axis suppression with three oral contraceptive regimens. Contraception77(3), 162–170 (2008).
   PubMed Web of Science ®Google Scholar
• Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst. Rev.3, CD004695 (2005).
   Google Scholar
• Fenton C, Wellington K, Moen MD, Robinson DM. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen), a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs67(12), 1749–1765 (2007).
   PubMed Web of Science ®Google Scholar
• Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception75(1), 16–22 (2007).
   PubMed Web of Science ®Google Scholar
• Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception68(2), 89–96 (2003).
   PubMed Web of Science ®Google Scholar
• Wilson SA, Kudis HA. Ethinyl estradiol/levonorgestrel (Seasonale) for oral contraception. Am. Fam. Physician.71(8), 1581–1582 (2005).
   Web of Science ®Google Scholar
• Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception73(3), 229–234 (2006).
   PubMed Web of Science ®Google Scholar
• Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results. Contraception74(6), 439–445 (2006).
   PubMed Web of Science ®Google Scholar
• Moreau C, Trussell J, Gilbert F, Bajos N, Bouyer J. Oral contraceptive tolerance: does the type of pill matter? Obstet. Gynecol.109, 1277–1285 (2007).
   PubMed Web of Science ®Google Scholar
• Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit. Progestogen-only pills. Faculty of Sexual and Reproductive Healthcare, London UK, June (2009).
   Google Scholar
• Grimes DA, Lopez LM, O’Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst. Rev.1, CD007541 (2010).
   Google Scholar
• WHO. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case–control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception57(5), 315–324 (1998).
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Lokkegaard, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ339, b2890 (2009).
   PubMed Web of Science ®Google Scholar